Literature DB >> 11171663

Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid.

O Ito1, K Omata, S Ito, K M Hoagland, R J Roman.   

Abstract

The effects of blockade of the renin-angiotensin system on the renal metabolism of arachidonic acid (AA) were examined. Male Sprague-Dawley rats were treated with vehicle, captopril (25 mg x kg(-1) x day(-1)), enalapril (10 mg x kg(-1) x day(-1)), or candesartan (1 mg x kg(-1) x day(-1)) for 1 wk. The production of 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) by renal cortical microsomes increased in rats treated with captopril by 59 and 24% and by 90 and 58% in rats treated with enalapril. Captopril and enalapril increased 20-HETE production in the outer medulla by 100 and 143%, respectively. In contrast, blockade of ANG II type 1 receptors with candesartan had no effect on the renal metabolism of AA. Captopril and enalapril increased cytochrome P-450 (CYP450) reductase protein levels in the renal cortex and outer medulla and the expression of CYP450 4A protein in the outer medulla. The effects of captopril on the renal metabolism of AA were prevented by the bradykinin-receptor antagonist, HOE-140, or the nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester. These results suggest that angiotensin-converting enzyme inhibitors may increase the formation of 20-HETE and EETs secondary to increases in the intrarenal levels of kinins and NO.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171663     DOI: 10.1152/ajpregu.2001.280.3.R822

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  8 in total

1.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

2.  Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism.

Authors:  Katherine N Theken; Yangmei Deng; Robert N Schuck; Akinyemi Oni-Orisan; Tricia M Miller; M Alison Kannon; Samuel M Poloyac; Craig R Lee
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-20       Impact factor: 4.310

3.  Androgen-induced hypertension in angiotensinogen deficient mice: role of 20-HETE and EETS.

Authors:  Victor Garcia; Jennifer Cheng; Adam Weidenhammer; Yan Ding; Cheng-Chia Wu; Fan Zhang; Katherine Gotlinger; John R Falck; Michal L Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-12-17       Impact factor: 3.072

4.  20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease.

Authors:  Frank Park; William E Sweeney; Guangfu Jia; Richard J Roman; Ellis D Avner
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

5.  20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells.

Authors:  Vani Nilakantan; Cheryl Maenpaa; Guangfu Jia; Richard J Roman; Frank Park
Journal:  Am J Physiol Renal Physiol       Date:  2008-01-02

6.  Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.

Authors:  Frank Park; William E Sweeney; Guangfu Jia; Talha Akbulut; Benjamin Mueller; J Russell Falck; Saritha Birudaraju; Richard J Roman; Ellis D Avner
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-07

Review 7.  Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein-Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches.

Authors:  Jonathan V Pascale; Pamela A Lucchesi; Victor Garcia
Journal:  J Cardiovasc Pharmacol       Date:  2021-06-01       Impact factor: 3.271

8.  Angiotensin converting enzyme inhibition reduces cardiovascular responses to acute stress in myocardially infarcted and chronically stressed rats.

Authors:  A Cudnoch-Jedrzejewska; K Czarzasta; L Puchalska; J Dobruch; O Borowik; J Pachucki; E Szczepanska-Sadowska
Journal:  Biomed Res Int       Date:  2014-06-19       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.